Skip to Content
Merck
  • Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy.

Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy.

The Journal of experimental medicine (2014-06-18)
Lei Wu, SuFey Ong, Monica V Talor, Jobert G Barin, G Christian Baldeviano, David A Kass, Djahida Bedja, Hao Zhang, Asfandyar Sheikh, Joseph B Margolick, Yoichiro Iwakura, Noel R Rose, Daniela Ciháková
ABSTRACT

Inflammatory dilated cardiomyopathy (DCMi) is a major cause of heart failure in individuals below the age of 40. We recently reported that IL-17A is required for the development of DCMi. We show a novel pathway connecting IL-17A, cardiac fibroblasts (CFs), GM-CSF, and heart-infiltrating myeloid cells with the pathogenesis of DCMi. Il17ra(-/-) mice were protected from DCMi, and this was associated with significantly diminished neutrophil and Ly6Chi monocyte/macrophage (MO/MΦ) cardiac infiltrates. Depletion of Ly6Chi MO/MΦ also protected mice from DCMi. Mechanistically, IL-17A stimulated CFs to produce key chemokines and cytokines that are critical downstream effectors in the recruitment and differentiation of myeloid cells. Moreover, IL-17A directs Ly6Chi MO/MΦ in trans toward a more proinflammatory phenotype via CF-derived GM-CSF. Collectively, this IL-17A-fibroblast-GM-CSF-MO/MΦ axis could provide a novel target for the treatment of DCMi and related inflammatory cardiac diseases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thrombopoietin human, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture, ≥98% (SDS-PAGE and HPLC)
Sigma-Aldrich
Diethyl azodicarboxylate solution, purum, ~40% in toluene (H-NMR)